Clinical Scorecard: Understanding the Limitations of CAR T Cell Therapy in Treating Renal Cell Carcinoma

At a Glance

Key Highlights

• CAR-T therapy has failed to produce durable clinical benefit in RCC despite antigen expression.
• Limited tumor trafficking and rapid functional decline of CAR-T cells are consistent across trials.
• Antigen recognition alone does not ensure therapeutic success in RCC.
• Environmental factors such as hypoxia and suppressive myeloid populations hinder CAR-T efficacy.

Guideline-Based Recommendations

Diagnosis

• Identify RCC-associated antigens for potential CAR-T targeting.

Management

• Consider alternative CAR-T constructs and delivery methods to improve safety and efficacy.

Monitoring & Follow-up

• Assess CAR-T cell persistence and functional activity within tumor tissue.

Risks

• Monitor for on-target, off-tumor toxicity and potential fratricide among CAR-T cells.

Patient & Prescribing Data

Patients with renal cell carcinoma undergoing CAR-T therapy.

Current CAR-T therapies show limited objective responses and intratumoral persistence.

Clinical Best Practices

Related Resources & Content

• Clinical studies on CAR-T therapy in RCC
• Mechanisms of CAR-T cell failure in solid tumors